KBC Group
TARS icon

KBC Group’s Tarsus Pharmaceuticals TARS Stock Holding History

KBC Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91K Hold
1,296
– – ﹤0.01% 1379
2025
Q4 		$106K Hold
1,296
– – ﹤0.01% 1235
2025
Q3 		$77K Buy
+1,296
New +$63.8K ﹤0.01% 1431

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

KBC Group's TARS Position: Q1 2026 in Review

KBC Group held its Tarsus Pharmaceuticals (TARS) position steady in Q1 2026 at 1,296 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

KBC Group first reported a position in TARS in Q3 2025 and has held it in 3 quarters since. The position peaked at $106K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • KBC Group held 1,296 shares of Tarsus Pharmaceuticals worth $91K as of Q1 2026.
  • KBC Group left its Tarsus Pharmaceuticals share count unchanged in Q1 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1379 holding.
  • KBC Group first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • KBC Group's Tarsus Pharmaceuticals position peaked at $106K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.